Clinical trial NCT00060385 (phase 2/phase 3, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: chop regimen, epoch regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
SMILES: CCO, CCO, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of diffuse large B-cell* or peripheral T-cell non-Hodgkin's lymphoma by
             REAL/WHO classification, including the following:

               -  All morphological and clinical variants

               -  All Ann Arbor stages NOTE: *Presence of a small cell, indolent lymphoma component
                  in the bone marrow biopsy is allowed

          -  No Burkitt-like lymphoma

          -  Previously untreated disease

          -  No cerebral or meningeal involvement

          -  At least 1 measurable target lesion at least 1.1 cm by the Cheson criteria

        PATIENT CHARACTERISTICS:

        Age

          -  70 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3 (unless related to bone marrow infiltration)

        Hepatic

          -  Bilirubin less than 1.8 mg/dL*

          -  AST or ALT less than 2.5 times upper limit of normal (ULN)*

          -  Alkaline phosphatase less than 4 times ULN* NOTE: *Values above these thresholds are
             allowed only if related to non-Hodgkin's lymphoma

        Renal

          -  Creatinine clearance at least 50 mL/min

        Cardiovascular

          -  LVEF at least 50%

        Other

          -  HIV negative

          -  No history of concurrent severe disease that would preclude study treatment

          -  No other prior or concurrent malignancy except adequately treated basal cell skin
             cancer, curatively treated carcinoma in situ of the cervix, or other curatively
             treated solid malignancy with no evidence of disease for at least 5 years prior to
             study entry

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No concurrent participation in another investigational drug study

          -  No other concurrent antineoplastic agents